United Kingdom : Alcon launches Jetrea in Canada to treat symptomatic vitreomacular.
As per to the company, Canada is the first market where Jetrea has been launched outside the US and Europe.
Marketing rights to commercialization of Jetrea, which has been sanctioned by Health Canada in August 2013 following priority review, has been purchased by Alcon, a division of Novartis, in March 2012.
Jetrea contains the active substance ocriplasmin and is administered through a one-time, single intravitreal injection to treat adults with symptomatic VMA.
Alcon in April 2013, presented the drug in the UK, its first European market after by launching in Germany, Denmark, Finland, Norway and Sweden.
ThromboGenics is commercializing Jetrea in the US and launched the drug in the US in mid-January 2013 where it is authorized for the cure of patients with symptomatic (VMA).
ThromboGenics CEO Patrik De Haes said that the launch of JETREA in Canada, the first market outside the US and Europe, for the treatment of symptomatic VMA.
De Haes said, "This is a condition where early pharmacological treatment is being seen as increasingly important in potentially preventing patients' loss of visual acuity which negatively impacts on their ability to carry out everyday tasks .
"We are looking forward to working with Alcon as it continues to roll out JETREA in other European and Rest of the World markets."
2013 Al Bawaba (Albawaba.com)
Provided by Syndigate.info an Albawaba.com company
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 23, 2013|
|Previous Article:||United Kingdom : ROLLS-ROYCE bags $138m contract from PETROBRAS.|
|Next Article:||United Kingdom : Patron Capital set for new Regent Street HQ.|